16 results on '"Peter Ping Lin"'
Search Results
2. Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC
- Author
-
Tongmei Zhang, Lina Zhang, Yuan Gao, Ying Wang, Yanxia Liu, Hongmei Zhang, Qunhui Wang, Fanbin Hu, Jie Li, Jinjing Tan, Daisy Dandan Wang, Olivier Gires, Peter Ping Lin, and Baolan Li
- Subjects
bevacizumab ,EMT and EndoMT ,EpCAM and vimentin ,prognosticators ,SE‐iFISH ,therapy efficacy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Prognosticating the efficacy of anti‐angiogenic therapy through longitudinal monitoring and early detection of treatment resistance in cancer patients remain highly challenging. In this study, co‐detection and comprehensive phenotypic and karyotypic molecular characterization of aneuploid circulating tumor cells (CTCs) and circulating tumor endothelial cells (CTECs) were conducted on non‐small cell lung cancer (NSCLC) patients receiving bevacizumab plus chemotherapy. Prognostic values of the cell‐based significant univariate risk factors identified by Cox regression analyses were progressively investigated. Subjects showing an increase in total post‐therapeutic platelet endothelial cell adhesion molecule‐1 (CD31)– CTCs and CD31+ CTECs exhibited a significantly reduced median progression‐free survival (mPFS) and overall survival. Further stratification analyses indicated that pretherapeutic patients bearing vimentin (Vim)+ CTECs (mesenchymal M‐type) at baseline revealed a significantly shortened mPFS compared with patients with Vim– CTECs. Post‐therapeutic patients harboring epithelial cell adhesion molecule (EpCAM)+ CTCs and CTECs (epithelial E‐type), regardless of Vim expression or not, showed a significantly reduced mPFS. Post‐therapeutic patients possessing de novo EpCAM+/Vim+ (hybrid E/M‐type) CTECs displayed the shortest mPFS. Patients harboring either pre‐ or post‐therapeutic EpCAM–/Vim– null CTECs (N‐type) exhibited a better response to therapy compared to patients harboring EpCAM+ and/or Vim+ CTECs. The presented results support the notion that baseline Vim+ CTECs and post‐therapeutic EpCAM+ CTCs and CTECs are predictive biomarkers for longitudinal monitoring of response to anti‐angiogenesis combination regimens in NSCLC patients.
- Published
- 2021
- Full Text
- View/download PDF
3. Case report: Post-therapeutic laryngeal carcinoma patient possessing a high ratio of aneuploid CTECs to CTCs rapidly developed de novo malignancy in pancreas
- Author
-
Jiaoping Mi, Fang Yang, Jiani Liu, Mingyang Liu, Alexander Y. Lin, Daisy Dandan Wang, Peter Ping Lin, and Qi Zeng
- Subjects
MRD ,prediction of cancer occurrence ,liquid biopsy ,aneuploid CTCs and CTECs ,SE-iFISH ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Effectively evaluating therapeutic efficacy, detecting minimal residual disease (MRD) after therapy completion, and predicting early occurrence of malignancy in cancer patients remain as unmet imperative clinical demands. This article presents a case of a laryngeal carcinoma patient who had a surgical resection and complete post-operative chemoradiotherapy in combination with the targeted therapy, then rapidly developed pancreatic adenocarcinoma. Detected by SE-iFISH, the patient had a substantial amount of 107 non-hematological aneuploid circulating rare cells including 14 circulating tumor cells (CTCs, CD31-/CD45-) and 93 circulating tumor endothelial cells (CTECs, CD31+/CD45-) with a high ratio of CTECs/CTCs > 5 upon finishing post-surgical combination regimens. Positive detection of those aneuploid non-hematological circulating rare cells was five months prior to subsequent plasma CA19-9 increasing and ten months before the de novo pancreatic cancer was diagnosed by medical imaging modalities. Besides previously reported clinical utilities of co-detection of aneuploid CD31- CTCs and CD31+ CTECs in real-time evaluation of therapeutic efficacy, longitudinal monitoring of emerging treatment resistance and adequate detection of MRD, a large cohort study is necessary to further investigate whether, and how, a high ratio of MRD CTECs to CTCs may function as an appropriate index forecasting either occurrence or metastatic distant recurrence of malignancy in post-therapeutic cancer patients.
- Published
- 2022
- Full Text
- View/download PDF
4. Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
- Author
-
Yang Hong, Jiahui Si, Jie Zhang, Ying Xiong, Jianzhi Zhang, Peter Ping Lin, Jian Fang, Yue Yang, Chao Lv, and Yuanyuan Ma
- Subjects
non-small cell lung cancer ,circulating aneuploid cells ,prognosis ,resection ,biomarker ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ObjectiveThe size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC).Patients and MethodsA total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.ResultsLess than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.ConclusionsPre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.
- Published
- 2021
- Full Text
- View/download PDF
5. Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis
- Author
-
Peter Ping Lin
- Subjects
aneuploid CTC ,aneuploid CTEC ,cellular circulating tumor biomarker ,endothelialization of cancer cells ,cancerization of stromal endothelial cells ,EMT ,Cytology ,QH573-671 - Abstract
Hematogenous and lymphogenous cancer metastases are significantly impacted by tumor neovascularization, which predominantly consists of blood vessel-relevant angiogenesis, vasculogenesis, vasculogenic mimicry, and lymphatic vessel-related lymphangiogenesis. Among the endothelial cells that make up the lining of tumor vasculature, a majority of them are tumor-derived endothelial cells (TECs), exhibiting cytogenetic abnormalities of aneuploid chromosomes. Aneuploid TECs are generated from “cancerization of stromal endothelial cells” and “endothelialization of carcinoma cells” in the hypoxic tumor microenvironment. Both processes crucially engage the hypoxia-triggered epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndoMT). Compared to the cancerization process, endothelialization of cancer cells, which comprises the fusion of tumor cells with endothelial cells and transdifferentiation of cancer cells into TECs, is the dominant pathway. Tumor-derived endothelial cells, possessing the dual properties of cancerous malignancy and endothelial vascularization ability, are thus the endothelialized cancer cells. Circulating tumor-derived endothelial cells (CTECs) are TECs shed into the peripheral circulation. Aneuploid CD31+ CTECs, together with their counterpart CD31- circulating tumor cells (CTCs), constitute a unique pair of cellular circulating tumor biomarkers. This review discusses a proposed cascaded framework that focuses on the origins of TECs and CTECs in the hypoxic tumor microenvironment and their clinical implications for tumorigenesis, neovascularization, disease progression, and cancer metastasis. Aneuploid CTECs, harboring hybridized properties of malignancy, vascularization and motility, may serve as a unique target for developing a novel metastasis blockade cancer therapy.
- Published
- 2020
- Full Text
- View/download PDF
6. Integrated EpCAM‐independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells
- Author
-
Peter Ping Lin
- Subjects
CTC and DTC subtype ,Heteroploid chromosome ,Tumor biomarker ,Metastasis ,Liquid biopsy ,Medicine (General) ,R5-920 - Abstract
AbstractApplication of tumor cell surface adhesion molecule EpCAM‐dependent antibody capture, and intracellular cytokeratins (CKs)‐dependent immunostaining strategies to detect disseminated or circulating tumor cells (DTCs or CTCs), is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs and DTCs, particularly in their capturing and identifying CTCs/DTCs shed from diverse types of solid tumor, thus being biased and restricted to the only both EpCAM and CK positive cancer cells. Moreover, heterogeneity of chromosome and tumor biomarker of CTCs/DTCs cannot be co‐examined by conventional CK/EpCAM‐dependent techniques. Accordingly, a novel integrated cellular and molecular approach of EpCAM‐independent subtraction enrichment (SE) and immunostaining‐FISH (iFISH®) has recently been successfully developed. SE‐iFISH® is able to effectively enrich, comprehensively identify and characterize both large and small size non‐hematopoietic heteroploid CTCs, DTCs and circulating tumor microemboli in various biofluid specimens of either cancer patients or patient‐derived‐xenograft mice. Obtained tumor cells, free of anti‐EpCAM perturbing and hypotonic damage, are eligible for primary tumor cell culture as well as a series of downstream analyses. Highly heterogeneous CTCs and DTCs could be classified into subtypes by in situ phenotyping protein expression of various tumor biomarkers and karyotyping of chromosome aneuploidy performed by iFISH®. Each CTC subtype may correlate with distinct clinical significance in terms of tumor metastasis, relapse, therapeutic drug sensitivity or resistance, respectively.
- Published
- 2015
- Full Text
- View/download PDF
7. Table S1-S6, and Figure S1-S4 from Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance
- Author
-
Lin Shen, Min Li, Peter Ping Lin, Xiaojuan Wang, Yanyan Li, Zhi Peng, Shan Li, Daisy Dandan Wang, Jifang Gong, Dan Liu, Xiaotian Zhang, and Yilin Li
- Abstract
Table S1. Clinical characteristics of assessable patients; Table S2. Cox analysis for prediction of progression-free survival (PFS) and overall survival (OS) in an histo-pathlogical HER2 positive (hHER2+) cohort; Table S3. Cox analysis for prediction of PFS and OS in an histo-pathological HER2 negative (hHER2-) cohort; Table S4. Quantified variation of HER2+/triploid CTCs and its correlation to prognosis; Table S5. Quantified variation of HER2+/tetraploid CTCs and its correlation to prognosis; Table S6. Cox analysis for prediction of PFS and OS for variation of HER2+/multiploid circulating tumor cells (CTCs); Figure S1. CONSORT flow chart; Figure S2. Quantification of HER2 expression on CTCs (cHER2) in gastric cancer (GC); Figure S3. Threshold of pre-therapeutic cHER2+ CTCs for predicting OS in the hHER2+ and hHER2- cohorts of patients with GC; Figure S4. Quantitative variation of aneuploid CTCs is in accordance with variation of HER2+ CTCs in patients from pre-therapy to progression.
- Published
- 2023
8. Data from Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance
- Author
-
Lin Shen, Min Li, Peter Ping Lin, Xiaojuan Wang, Yanyan Li, Zhi Peng, Shan Li, Daisy Dandan Wang, Jifang Gong, Dan Liu, Xiaotian Zhang, and Yilin Li
- Abstract
Purpose: Previous human epidermal growth factor receptor-2 (HER2)-derived resistance studies were based on ex vivo models, which could not mirror evolutionary expression of HER2 during therapy. To investigate dynamic expression of HER2 and its contribution to developing therapeutic resistance conferred by chromosome aneuploidy, both the HER2 phenotype and chromosome 8 (Chr 8) aneuploidy on circulating tumor cells (CTC) were coexamined in advanced gastric cancer (AGC) patients.Experimental Design: A total of 115 AGC patients, including 56 of histopathologic HER2+ (hHER2+) subjects who received first-line HER2-targeted therapy plus chemotherapy, and 59 of hHER2− patients who received chemotherapy alone, were prospectively enrolled. Both HER2 phenotype and Chr8 aneuploidy of CTCs in patients were coexamined by HER2-iFISH during therapy.Results: A fluctuated positive HER2 phenotype on CTCs (cHER2+) was revealed, showing cHER2+ at different time intervals during treatment. Acquisition of the cHER2+ phenotype in 91.0% of hHER2+ and 76.2% hHER2− patients was demonstrated to correlate with development of resistance to trastuzumab-targeted therapy for hHER2+ patients and chemotherapy alone for hHER2− patients. Aneuploid Chr8 was demonstrated to participate in the acquisition of the cHER2+ phenotype, which provides a growth advantage to HER2+ CTCs against therapeutic pressure, leading to the development of therapeutic resistance.Conclusions: Compared with low positivity of conventional histopathologic hHER2 examination routinely performed once, significant higher positivity of cHER2+ on CTCs was observed. Continuously examining cHER2 shows unique advantages with respect to monitoring therapeutic resistance in real time in carcinoma patients. Moreover, contribution of chromosome aneuploidy to the phenotypic evolution of HER2 expression on CTCs may help elucidate underlying mechanisms of developing therapeutic resistance. Clin Cancer Res; 24(21); 5261–71. ©2018 AACR.
- Published
- 2023
9. Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
- Author
-
Mingxiao Li, Faliang Gao, Xiaohui Ren, Gehong Dong, Hongyan Chen, Alexander Y. Lin, Daisy Dandan Wang, Mingyang Liu, Peter Ping Lin, Shaoping Shen, Haihui Jiang, Chuanwei Yang, Xiaokang Zhang, Xuzhe Zhao, Qinghui Zhu, Ming Li, Yong Cui, and Song Lin
- Subjects
Cancer Research ,Endothelial Cells ,General Medicine ,Glioma ,Aneuploidy ,Neoplastic Cells, Circulating ,Prognosis ,ErbB Receptors ,Oncology ,Drug Resistance, Neoplasm ,Glial Fibrillary Acidic Protein ,Biomarkers, Tumor ,Humans ,In Situ Hybridization, Fluorescence - Abstract
Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize aneuploid CACs, including CD31
- Published
- 2022
10. Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer
- Author
-
Zheng Li, Liwen Fan, Yun Wu, Yuxu Niu, Xuelin Zhang, Bin Wang, Yuanshan Yao, Chunji Chen, Ning Qi, Daisy Dandan Wang, Peter Ping Lin, Dongfang Tang, and Wen Gao
- Subjects
Pulmonary and Respiratory Medicine ,hemic and lymphatic diseases ,Original Article ,neoplasms - Abstract
BACKGROUND: Recently, circulating tumor-cell-associated white blood cell (CTC-WBC) clusters have been reported to have prognostic value in some cancers. The prognostic role of CTC-WBC clusters in lung cancer has not yet been elucidated. Very little information is available about the biological characteristics of CTC-WBC clusters. METHODS: A total of 82 patients with non-small cell lung cancer (NSCLC) were included in this study, and 61 patients with advanced-stage disease were closely followed-up. All patients had blood drawn prior to treatment. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was used to isolate and identify CTCs and CTC-WBC clusters. Kaplan-Meier survival analysis and Cox regression analysis were applied to assess patient progression-free survival (PFS). Further, qualitative and quantitative analyses the size and ploidy characteristics of CTC-WBC clusters. RESULTS: Firstly, CTC‐WBC clusters appeared more in the advanced (stage III and IV) stage (P=0.043) than in the early stage. Furthermore, the multivariable analysis (Cox proportional hazards model) revealed that the high‐CTC (≥7/6 mL) group and CTC‐WBC clusters (≥1/6 mL) positive group both had significantly worse PFS, with a hazard ratio (HR) of 2.89 [95% confidence interval (CI): 1.36–6.17, P=0.006] and 2.18 (95% CI: 1.07–4.43, P=0.031), respectively. In the conjoint analysis, compared to patients with
- Published
- 2022
11. Longitudinal Detection of CD44v6 Circulating Tumor Cells Facilitates Risk Stratification of Small-Cell Lung Cancer: A Prospective, Non-Interventional, Multi-Center Study
- Author
-
Ying Wang, Lina Zhang, Zhiyun Zhang, Yanxia Liu, Xingsheng Hu, Baohua Lu, Yuan Gao, Li Tong, Zan Liu, Hongxia Zhang, Peter Ping Lin, Baolan Li, Olivier Gires, and Tongmei Zhang
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
12. Identification and Comprehensive Co-Detection of Necrotic and Viable Aneuploid Cancer Cells in Peripheral Blood
- Author
-
Daisy Dandan Wang, Linda Li, Alexander Y. Lin, and Peter Ping Lin
- Subjects
Cancer Research ,liquid biopsy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,medicine.disease ,Malignancy ,medicine.disease_cause ,Minimal residual disease ,Article ,rapid evaluation of therapeutic effects ,Circulating tumor cell ,MRD ,Oncology ,Cancer cell ,medicine ,Carcinoma ,Cancer research ,Liquid biopsy ,Carcinogenesis ,business ,SE-iFISH ,RC254-282 ,necrotic CTCs and CTECs - Abstract
Simple Summary Circulating tumor cells (CTCs) and CD31+ circulating tumor endothelial cells (CTECs) constitute a unique pair of cellular circulating tumor biomarkers and play a crucial role in cancer metastasis and disease progression. Precise detection of live and necrotic aneuploid CTCs and CTECs in therapeutic cancer patients, though clinically highly demanded, has yet to be achieved in the field. The aim of this study is to develop a comprehensive strategy to effectively distinguish and co-detect viable and dead non-hematological cancer cells harboring aneuploid chromosomes and expressing various tumor markers. The innovative strategy developed in the present study will assist in an efficient assessment of therapy effectiveness, rapid detection of emerging treatment resistance and bringing in new insights into the comprehension of cancer cells in circulation. Abstract Aneuploid circulating tumor cells (CTCs, CD31−) and circulating tumor endothelial cells (CTECs, CD31+) exhibit an active interplay in peripheral blood, and play an essential role in tumorigenesis, neoangiogenesis, disease progression, therapy-resistant minimal residual disease (MRD), cancer metastasis and relapse. Currently, most CTC detection techniques are restricted to the indistinguishable quantification of circulating rare cells, including both necrotic and viable cells in cancer patients. Clinically imperative demands to distinguish and detect live and/or dead non-hematological aneuploid cancer cells in peripheral blood, which will assist in the rapid evaluation of therapeutic effects, real-time monitoring of treatment resistance longitudinally developed along with therapy and the effective detection of post-therapeutic MRD, have not yet been achieved. The integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)-derived novel strategy was developed in this study, aiming to precisely identify and detect live and necrotic cancer cells (NC) enriched from carcinoma patients’ biofluids. The innovative SE-iFISH (NC) provides a meaningful and practical approach to co-detect various viable and necrotic aneuploid CTCs and CTECs. The detected circulating rare cells can be characterized and categorized into diverse subtypes based upon cell viability, morphology, multiple tumor markers’ expression, and the degree of aneuploidy relevant to both malignancy and therapeutic resistance. Each subtype of live or necrotic CTCs and CTECs possesses distinct utility in anti-cancer drug development, translational research, and clinical practice.
- Published
- 2021
13. Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
- Author
-
Fangliang Lu, Daisy Dandan Wang, Chao Lv, Peter Ping Lin, Shanyuan Zhang, Miao Huang, Yuanyuan Ma, Yue Yang, and Shaolei Li
- Subjects
Oncology ,Cisplatin ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Surrogate endpoint ,medicine.medical_treatment ,therapeutic response ,Tumor Cell Necrosis ,Aneuploidy ,International Journal of General Medicine ,General Medicine ,medicine.disease ,circulating tumor cell ,Circulating tumor cell ,non-small-cell lung cancer ,Response Evaluation Criteria in Solid Tumors ,Internal medicine ,medicine ,Lung cancer ,business ,medicine.drug ,Original Research ,neoadjuvant chemotherapy - Abstract
Miao Huang,1,* Yuanyuan Ma,1,* Chao Lv,1 Shaolei Li,1 Fangliang Lu,1 Shanyuan Zhang,1 Daisy Dandan Wang,2 Peter Ping Lin,2 Yue Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, Peopleâs Republic of China; 2Department of Oncology, Cytelligen, San Diego, CA, USA*These authors contributed equally to this workCorrespondence: Yue YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, Peopleâs Republic of ChinaTel +86 10 8819 6568Email yangyue236@outlook.comPurpose: This study aimed to explore the potential application of circulating tumor cells (CTCs) in predicting the therapeutic effect of neoadjuvant chemotherapy (NAC) in non-small-cell lung cancer (NSCLC).Methods: Using integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization, the serial CTCs of patients with NSCLC were detected in 7.5 mL of blood at baseline and after two cycles of cisplatin-based NAC, and all aneuploidies of chromosome 8 were examined in the enriched CTCs. Tumor responses were evaluated radiologically with serial chest computed tomography (CT) using the response evaluation criteria in solid tumors and microscopically using the tumor cell necrosis rate (TCNR) of the resected specimen after NAC.Results: After two cycles of cisplatin-based NAC, 89% (8/9) of the patients with radiological partial response to NAC had reduced CTC numbers, while 73% (8/11) of the patients with stable disease exhibited increased CTC numbers (P = 0.0098). On pathological examination, 90% (9/10) of patients with a TCNR lower than 30% had > 1 CTC post-NAC, while 80% (4/5) of patients with a TCNR higher than 30% had ⤠1 CTC post-NAC (P = 0.017). In aneuploidy analysis, the positive rate (CTC > 0) of triploid CTCs was found to have increased after NAC, in contrast with the tetraploid and multiploid CTCs. Furthermore, tetraploid and multiploid CTCs were found to be significantly downregulated in the patients with partial response to NAC.Conclusion: The correlations of aneuploid CTCs with both radiological and pathological responses in patients with NSCLC who received NAC were summarized, and the findings indicate that enumerating and karyotyping aneuploid CTCs can serve as a surrogate marker for disease monitoring in NSCLC.Keywords: non-small-cell lung cancer, circulating tumor cell, neoadjuvant chemotherapy, therapeutic response
- Published
- 2021
14. Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
- Author
-
Jianzhi Zhang, Yang Hong, Jian Fang, Chao Lv, Peter Ping Lin, Jiahui Si, Yue Yang, Ying Xiong, Yuanyuan Ma, and Jie Zhang
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,circulating aneuploid cells ,medicine ,Clinical significance ,cardiovascular diseases ,resection ,Stage (cooking) ,Lung cancer ,non-small cell lung cancer ,Original Research ,medicine.diagnostic_test ,Large cell ,nutritional and metabolic diseases ,Karyotype ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,biomarker ,prognosis ,Immunostaining ,Fluorescence in situ hybridization - Abstract
ObjectiveThe size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC).Patients and MethodsA total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.ResultsLess than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.ConclusionsPre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.
- Published
- 2020
15. PD-L1
- Author
-
Lina, Zhang, Xinyong, Zhang, Yanxia, Liu, Tongmei, Zhang, Ziyu, Wang, Meng, Gu, Yilin, Li, Daisy Dandan, Wang, Weiying, Li, and Peter Ping, Lin
- Subjects
Male ,Neovascularization, Pathologic ,Programmed Cell Death 1 Receptor ,Endothelial Cells ,Middle Aged ,Aneuploidy ,Neoplastic Cells, Circulating ,B7-H1 Antigen ,Progression-Free Survival ,Nivolumab ,Drug Resistance, Neoplasm ,Carcinoma, Non-Small-Cell Lung ,Biomarkers, Tumor ,Disease Progression ,Tumor Microenvironment ,Humans ,Female ,Immunotherapy - Abstract
Sustained angiogenesis and increased PD-L1 expression on endothelial and carcinoma cells contribute toward fostering an immunosuppressive microenvironment suitable for tumor growth. PD-L1
- Published
- 2019
16. Quantified postsurgical small cell size CTCs and EpCAM
- Author
-
Liang, Wang, Yilin, Li, Jing, Xu, Aiqun, Zhang, Xuedong, Wang, Rui, Tang, Xinjing, Zhang, Hongfang, Yin, Manting, Liu, Daisy Dandan, Wang, Peter Ping, Lin, Lin, Shen, and Jiahong, Dong
- Subjects
Adult ,Chromosome Aberrations ,Male ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Neoplastic Stem Cells ,Humans ,Female ,Middle Aged ,Neoplasm Recurrence, Local ,Epithelial Cell Adhesion Molecule ,Neoplastic Cells, Circulating ,Aged - Abstract
Detection of hepatocellular carcinoma circulating tumor cells performed with conventional strategies, is significantly limited due to inherently heterogeneous and dynamic expression of EpCAM, as well as degradation of cytokeratins during epithelial-to-mesenchymal transition, which inevitably lead to non-negligible false negative detection of such "uncapturable and invisible" CTCs. A novel SE-iFISH strategy, improved for detection of HCC CTCs in this study, was applied to comprehensively detect, in situ phenotypically and karyotypically characterize hepatocellular and cholangiocarcinoma CTCs (CD45
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.